The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines given in the U.S. this ...

The agency said it will evaluate whether regulatory action is needed after investigating the deaths of two patients treated ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million ...